Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. raised its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 7.8% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,491,514 shares of the company's stock after purchasing an additional 323,831 shares during the period. Envestnet Asset Management Inc. owned 0.10% of Novo Nordisk A/S worth $311,891,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Victory Capital Management Inc. raised its holdings in Novo Nordisk A/S by 58.5% during the 4th quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock valued at $5,410,000 after buying an additional 23,223 shares during the period. North Star Investment Management Corp. raised its stake in shares of Novo Nordisk A/S by 18.2% during the first quarter. North Star Investment Management Corp. now owns 20,742 shares of the company's stock valued at $1,440,000 after acquiring an additional 3,200 shares in the last quarter. Stanley Laman Group Ltd. bought a new position in shares of Novo Nordisk A/S during the 1st quarter worth $390,000. Dover Advisors LLC bought a new position in Novo Nordisk A/S during the 1st quarter worth about $505,000. Finally, Natural Investments LLC purchased a new position in Novo Nordisk A/S during the fourth quarter valued at approximately $1,345,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Trading Up 0.2%

Shares of NYSE NVO traded up $0.16 during trading on Wednesday, hitting $69.80. 5,372,841 shares of the company were exchanged, compared to its average volume of 7,292,013. The company has a fifty day moving average price of $70.19 and a 200-day moving average price of $75.37. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74. The firm has a market capitalization of $311.66 billion, a PE ratio of 20.65, a P/E/G ratio of 1.36 and a beta of 0.64. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $143.49.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The business had revenue of $11.87 billion for the quarter. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Wall Street Analyst Weigh In

NVO has been the subject of several analyst reports. BNP Paribas initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating for the company. BMO Capital Markets reissued a "market perform" rating and issued a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Finally, Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.